Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Golden Meditech Gains US OK for Houston T-Cell Processing Center

publication date: Feb 7, 2018

Golden Meditech of Hong Kong reported that Cellenkos, its Houston, Texas subsidiary, was granted Good Manufacturing Status by the FDA for a T-Cell processing facility. The facility processes cord blood-derived regulatory T-cells that will be tested as immune system suppressors in several autoimmune diseases. Last year, Golden Meditech formed a partnership with M.D. Anderson Hospital and a private investor to back Cellenkos and its processing facility. Previously, Golden Meditech was involved with China Cord Blood, a cord blood banking company, which it sold for $737 million in 2017. More details....

Stock Symbol: (HK: 00801)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.